SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Moyo-Gwete, Thandeka, Madzivhandila, Mashudu, Makhado, Zanele, Ayres, Frances, Mhlanga, Donald, Oosthuysen, Brent, Lambson, Bronwen E., Kgagudi, Prudence, Tegally, Houriiyah, Iranzadeh, Arash, Doolabh, Deelan, Tyers, Lynn, Chinhoyi, Lionel R., Mennen, Mathilda, Skelem, Sango, Marais, Gert, Wibmer, Constantinos Kurt, Bhiman, Jinal N, Ueckermann, Veronica, Rossouw, Theresa, Boswell, Michael, de Oliveira, Tulio, Williamson, Carolyn, Burgers, Wendy A, Ntusi, Ntobeko, Morris, Lynn, Moore, Penny L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941631/
https://www.ncbi.nlm.nih.gov/pubmed/33688657
http://dx.doi.org/10.1101/2021.03.06.434193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941631/
https://www.ncbi.nlm.nih.gov/pubmed/33688657
http://dx.doi.org/10.1101/2021.03.06.434193

Ejemplares similares